Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma’s obesity drug candidate.
Roche, Zealand Pharma Partner to Co-Develop & Co-Commercialize Obesity Therapy
Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will collaborate to co-develop & co-commercialize petrelintide.
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide.
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Yahoo Finance24d
Zealand Pharma convenes its Annual General Meeting 2025
Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of ...
MoneyWeek on MSN9d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Former CDC nominee goes scorched earth, blaming two Republicans and ‘big Pharma’ for failed bid
Weldon’s nomination to head the CDC was withdrawn just 12 hours before he was supposed to testify to the Senate health ...
Yahoo Finance24d
Zealand Pharma Announces Financial Results for the Full Year 2024
Driving innovation in obesity with differentiated mid- to late-stage pipeline “2024 was a transformational year for Zealand Pharma with positive data across our mid- to late-stage obesity ...
Nasdaq24d
Zealand Pharma FY24 Loss Widens
(RTTNews) - Biotechnology company Zealand Pharma A/S (ZEAL, ZLPDF.OB) recorded wider net loss for the full year, that reflected lower revenues and higher operating expenses. The company posted net ...
Seeking Alpha23d
Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript
Welcome to the Zealand Pharma Results for Full Year 2024 Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today Anna Krassowska, Head of ...
Benzinga.com17d
7 Analysts Have This To Say About NewAmsterdam Pharma
In the last three months, 7 analysts have published ratings on NewAmsterdam Pharma NAMS, offering a diverse range of perspectives from bullish to bearish. The following table encapsulates their ...